anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Nuvalent · pitchdeck

Nuvalent | Investor Presentation Deck | 39 slides

39 pages · 5 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Nuvalent | Investor Presentation Deck | 39 slides

Nuvalent · 2023-05
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 16 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Competition 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Traction 12 slides 100% 12/12 slides 100% 12/12 slides · 53 hits
— 0/12 slides
25% 3/12 slides
— 0/12 slides
100% 12/12 slides 100% 12/12 slides · 24 hits

Slide inventory

39
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a visual bracket system to connect the main headline to three pillars.inspire_vision
Open slide detail
04
The slide is split into a 2022 review on the left and a corporate vision statement on the right.summarize
Open slide detail
05
Includes a grid of headshots for the leadership team and lists for board members and advisors, plus a logo-grid for prior FDA approvals.other
Open slide detail
06
Uses a Venn diagram to illustrate the intersection of two key clinical challenges.present_solution
Open slide detailBeat · Solution
07
Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
08
Uses a visual comparison framework to contrast 'non-selective' vs 'selective' mechanisms.present_solution
Open slide detailLoop · Cost Of Inaction
09
The slide uses a list of icons to represent key clinical attributes of the drug candidate.present_solution
Open slide detailLoop · Cost Of Inaction
10
The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.size_opportunity
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
11
The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').compare_peers
Open slide detailBeat · CompetitionLoop · Cost Of Inaction
12
The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.frame_problem
Open slide detailLoop · Cost Of Inaction
13
The slide uses dot plots for IC50 data and a bar chart for in vivo efficacy, highlighting NVL-520's performance.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
14
The slide uses two distinct chart types to demonstrate efficacy: a bar chart for brain penetrance and a grouped bar chart for selectivity index.present_solution
Open slide detailBeat · TractionLoop · Cost Of Inaction
15
Includes a detailed table of Phase 2 cohorts and a list of study objectives.present_framework
Open slide detailBeat · TractionLoop · Cost Of Inaction
16
The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.analyze_data
Open slide detailBeat · TractionLoop · Cost Of Inaction
17
Data table showing demographics, tumor types, ECOG performance status, and prior treatment history including specific TKI therapies.analyze_data
Open slide detailBeat · TractionLoop · Cost Of Inaction
18
Data as of 13 Sep 22. Table lists specific adverse events by grade.analyze_data
Open slide detailBeat · TractionLoop · Cost Of Inaction
19
The chart displays dose-dependent exposure levels exceeding multiple target thresholds for ROS1 variants in CNS and periphery.analyze_data
Open slide detailBeat · TractionLoop · Cost Of Inaction
20
Clinical trial data table showing efficacy metrics for a drug candidate.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
22
The chart is a swimmer plot, commonly used in oncology clinical trials to visualize time-to-event data.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
23
Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
24
Includes MRI scan series showing lesion reduction over 8 weeks.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
25
Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.illustrate_case
Open slide detailLoop · Cost Of Inaction
26
Clinical trial summary slide for Nuvalent's ARROS-1 study.summarize
Open slide detailLoop · Cost Of Inaction
27
The slide uses a list format to define the TPP, which is a standard pharmaceutical industry framework.present_solution
Open slide detail
28
The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.size_opportunity
Open slide detail
29
The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.compare_peers
Open slide detail
30
The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.present_solution
Open slide detail
31
The slide compares vehicle control against NVL-655 treatment in both bar chart (multiple models) and line chart (PDX model) formats.show_traction
Open slide detail
32
The slide outlines the study design for NVL-655, including dose levels for Phase 1 and specific inclusion criteria for Phase 2 cohorts (2a-2d).plan_implementation
Open slide detail
33
The slide outlines the key therapeutic advantages of the drug candidate NVL-330.present_solution
Open slide detail
34
Includes three distinct charts: a dot plot for IC50, a bar chart for selectivity index, and a bar chart for brain penetrance.present_solution
Open slide detail
35
transition
Open slide detail
36
The slide uses a diagonal process flow with hexagonal containers.present_framework
Open slide detail
37
The slide uses a standard pharmaceutical pipeline visualization format.plan_implementation
Open slide detail
38
Includes a 3D molecular structure visualization.summarize
Open slide detail
39
Includes a molecular structure visualization.front_matter
Open slide detail